Many phase II clinical studies in oncology use two-stage frequentist design such as Simon\u27s optimal design. However, they have a common logistical problem regarding the patient accrual at the interim. Strictly speaking, patient accrual at the end of the first stage may have to be suspended until all patients have events, success or failure. For example, when the study endpoint is six-month progression free survival, patient accrual has to be stopped until all outcomes from stage I is observed. However, study investigators may have concern when accrual is suspended after the first stage due to the loss of accrual momentum during this hiatus. We propose a two-stage phase II design that resolves the patient accrual problem due to an interim...
Clinical trials play vital roles in drug development. Traditionally, phase II and phase III studies ...
Early phase clinical trial designs have long been the focus of interest for clinicians and statistic...
The main purpose of a single-arm phase II cancer trial of a new regimen is to determine whether it ...
Many phase II clinical studies in oncology use two-stage frequentist design such as Simon\u27s optim...
The rate of failure in phase III oncology trials is surprisingly high, partly due to inadequate phas...
Abstract Background Phase II cancer studies are undertaken to assess the activity of a new drug or a...
Background: For most cytotoxic and biologic anti-cancer agents, the response rate of the drug is com...
Single-arm two-stage designs for phase II of clinical trials typically focus on a binary endpoint ob...
AbstractTwo-stage designs are commonly used in phase II oncology trial to mitigate the risk of expos...
Recent scientific advances in biomedical research have rapidly increased the number of promising new...
Phase II clinical trials are a critical aspect of the drug development process. With drug developmen...
Trials run in either rare diseases, such as rare cancers, or rare subpopulations of common diseases ...
AbstractThe Simon two-stage optimal design is often used for phase II cancer clinical trials. A stud...
Single-arm two-stage designs for phase II of clinical trials typically focus on a binary endpoint ob...
Two-stage designs that allow for early stopping if the treatment is ineffective are commonly used in...
Clinical trials play vital roles in drug development. Traditionally, phase II and phase III studies ...
Early phase clinical trial designs have long been the focus of interest for clinicians and statistic...
The main purpose of a single-arm phase II cancer trial of a new regimen is to determine whether it ...
Many phase II clinical studies in oncology use two-stage frequentist design such as Simon\u27s optim...
The rate of failure in phase III oncology trials is surprisingly high, partly due to inadequate phas...
Abstract Background Phase II cancer studies are undertaken to assess the activity of a new drug or a...
Background: For most cytotoxic and biologic anti-cancer agents, the response rate of the drug is com...
Single-arm two-stage designs for phase II of clinical trials typically focus on a binary endpoint ob...
AbstractTwo-stage designs are commonly used in phase II oncology trial to mitigate the risk of expos...
Recent scientific advances in biomedical research have rapidly increased the number of promising new...
Phase II clinical trials are a critical aspect of the drug development process. With drug developmen...
Trials run in either rare diseases, such as rare cancers, or rare subpopulations of common diseases ...
AbstractThe Simon two-stage optimal design is often used for phase II cancer clinical trials. A stud...
Single-arm two-stage designs for phase II of clinical trials typically focus on a binary endpoint ob...
Two-stage designs that allow for early stopping if the treatment is ineffective are commonly used in...
Clinical trials play vital roles in drug development. Traditionally, phase II and phase III studies ...
Early phase clinical trial designs have long been the focus of interest for clinicians and statistic...
The main purpose of a single-arm phase II cancer trial of a new regimen is to determine whether it ...